SEC Comment Letter 0000000000-24-000700 to IntelGenx Technologies Corp. (IGXT) (CIK 0001098880)
IntelGenx Technologies Corp. (IGXT) (CIK 0001098880)
Date: Jan. 18, 2024 · CIK: 0001098880 · Accession: 0000000000-24-000700
AI Filing Summary & Sentiment
File numbers found in text: 024-12386
Letter
United States securities and exchange commission logo January 18, 2024 Dwight Gorham Chief Executive Officer IntelGenx Technologies Corp. 6420 Abrams Saint Laurent, Quebec H4S 1Y2, Canada Re:IntelGenx Technologies Corp. Offering Statement on Form 1-A Filed January 9, 2024 File No. 024-12386 Dear Dwight Gorham: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Raymer
Show Raw Text
United States securities and exchange commission logo
January 18, 2024
Dwight Gorham
Chief Executive Officer
IntelGenx Technologies Corp.
6420 Abrams
Saint Laurent, Quebec
H4S 1Y2, Canada
Re:IntelGenx Technologies Corp.
Offering Statement on Form 1-A
Filed January 9, 2024
File No. 024-12386
Dear Dwight Gorham:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Richard Raymer